With the COVID-19 pandemic, clinicians, researchers, industry leaders, and federal regulators in oncology have had to adapt to an evolving landscape of patient care and trial management. At the 2021 Society for Immunotherapy of Cancer Annual Meeting, several experts discussed some of the lessons learned along the way, and advocated for more decentralized, or virtual, clinical trials.

You do not currently have access to this content.